

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Pablo Rubinstein, Philip Henry Coelho,
and Cladd E. Stevens

Serial No. : To Be Assigned

Filed : May 15, 2001

For : HIGH CONCENTRATION WHITE CELLS, A METHOD FOR
AGGLOMERATION OF THE HIGH CONCENTRATION AND A
BAG SET FOR USE IN CONJUNCTION THEREWITH

"Express Mail" mailing label No. EL613247211USDate of Deposit: May 15, 2001

I hereby certify that this paper or fee is being
deposited with the United States Postal Service
"Express Mail Post Office to Addressee" service under
37 CFR 1.10 on the date indicated above and is
addressed to the Commissioner for Patents,
Washington, D.C. 20231.

Name: Lisa M. MelansonSignature: Lisa Melanson**PRELIMINARY AMENDMENT**

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the above-identified application as follows:

In the Specification:

At page 2, before "FIELD OF THE INVENTION", please add the following
paragraph:

This is a continuation of co-pending U.S. Application Serial No. 09/313,816,
filed May 18, 1999, which in turn is a continuation of U.S. Application Serial No.
09/128,208, filed August 3, 1998, which in turn is a continuation of U.S. Application No.
08/349,747, filed December 5, 1994, and now issued as U.S. Patent No. 5,789,147, the
contents of which are incorporated herein by reference.

Applicants : Pablo Rubinstein, Philip Henry Coelho,
and Cladd E. Stevens
Serial No. : To Be Assigned
Filed : May 15, 2001
Page 2

In the Claims:

Please cancel Claims 1-24 without prejudice to applicants' right to pursue prosecution of these claims in a later-filed continuation or divisional application.

Please add new Claims 25-32 as follows:

25. (new) A therapeutic product obtained from cord blood or placental blood, said product comprising white blood cells having a white cell viability greater than 80% of said white cell viability in said cord blood or placental blood, and less than all of plasma contained in said blood.

26. (new) The therapeutic product of Claim 25, further including a cryoprotective agent.

27. (new) The therapeutic product of Claim 26, wherein said cryoprotective agent comprises dimethyl sulfoxide.

28. (new) The therapeutic product of Claim 26, wherein said cryoprotective agent comprises dextran.

29. (new) The therapeutic product of Claim 27, wherein said dimethyl sulfoxide is diluted to 50% with dextran.

30. (new) The therapeutic product of Claim 27, wherein a concentration of said dimethyl sulfoxide is not greater than 10%.

Applicants : Pablo Rubinstein, Philip Henry Coelho,
and Cladd E. Stevens
Serial No. : To Be Assigned
Filed : May 15, 2001
Page 3

31. (new) The therapeutic product of Claim 27, wherein a concentration of said dimethyl sulfoxide is not greater than 1%.


32. (new) The therapeutic product of Claim 27, wherein an osmolarity of said product is not more than 300 milliosmols.

No fee is deemed necessary in connection with the filing of this Preliminary Amendment. If any fee is required, authorization is hereby given to charge any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN
Attorneys for Applicants
90 Park Avenue
New York, New York 10016
(212) 697-5995

Dated: New York, New York
May 15, 2001

By 
Craig J. Arnold
Registration No. 34,287